Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion type Assertion NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_head.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion description "[Somatic TET2 mutations are frequently observed in myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes including chronic myelomonocytic leukaemia (CMML), acute myeloid leukaemias (AML) and secondary AML (sAML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_provenance.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion evidence source_evidence_literature NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_provenance.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion SIO_000772 21057493 NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_provenance.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion wasDerivedFrom befree-20140225 NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_provenance.
- NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_assertion wasGeneratedBy ECO_0000203 NP449267.RAM4f5NpCitQOPE7iBtTxpBXnzNBJ3H-w4hcHlInYUI28130_provenance.